Diabetes mellitus & ndash; heterogeneous syndrome caused by absolute (type 1 diabetes) or relative (type 2 diabetes) insulin deficiency, which initially causes a violation of carbohydrate metabolism, and then all types of metabolism, which ultimately leads to the defeat of all functional systems of the body.
Type 1 diabetes
It is an autoimmune disease in which & nbsp; destruction of the beta cells of the islets of Langerhans and the development of absolute insulin deficiency. Patients can be of any age, but more often they are younger patients up to 30 years old and children..
Type 2 diabetes
Type 2 diabetes is caused by a combination of two main factors: insulin resistance and insulin secretion deficiency, the ratio of which is subject to significant fluctuations in a single patient, which naturally dictates the need for an individual approach to the treatment of diabetes. Type 2 diabetes is most common in people over 40 years of age. However, in recent years, diabetes mellitus type 2, more often than previously diagnosed in children
"Medical On Group Investment" пConducting research in the treatment of diabetes and the prevention of cardiovascular complications. The first off-peak analogue of insulin of long 24-hour action - insulin & nbsp; has been developed and received wide practical application. glargine Lantus. Oral hypoglycemic drug for the treatment of type 2 diabetes mellitus - glimepiride & nbsp; is actively used in clinical practice. Amaril. In the near future, an analogue of ultrashort-acting insulin, insulin glulisine apidra, will enter the market. Developed by & nbsp; drugs that act on the process of regulating glycemia level (glycogen phosphorylase inhibitor, DPP & ndash; IV inhibitor, PPAR-agonist ...)
In addition to diabetes, Medical On Group Investment strong> explores other metabolic disorders. The target diseases in this area of medicine for us are & nbsp; dyslipidemia (impaired fat metabolism), hypercholesterolemia, obesity and other metabolic risk factors for cardiovascular diseases.